INO

INOVIO PHARMACEUTICALS, INC. INO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,840 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-6.01M

Quarter to Jun 30

Free cash flow

$-18.05M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$36.33M total
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/INO

Earnings Per Share

13fpro.ai/company/INO

Loading ratio trend…

INO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About INOVIO PHARMACEUTICALS, INC. (INO): stock profile, AI score and financials

INOVIO PHARMACEUTICALS, INC. (INO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INO at 13.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,840 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), INOVIO PHARMACEUTICALS, INC. reports net income of $-6.0M, free cash flow of $-18.0M. INO trades on the Nasdaq exchange and files with the SEC under CIK 1055726. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INOVIO PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1055726 →